S100B and Parkinson disease: The link between S100B and catecholaminergic neurotransmitters has been underlined by diverse studies: S100B might modulate the expression of DA D2 receptor [28,29]; in rat models of Parkinson’s disease, depletion of striatal DA was followed by morphological changes in S100B-expressing astrocytes and increased S100B concentrations [30]; S100B-knockout mice were found to have significantly decreased levels of NE in the neocortex and hippocampus in comparison with wild-type mice [31].